Hemophilia Strategic Partnership Lead

Summary The Hemophilia Strategic Partnership Lead is a senior commercial role responsible for the growth and long-term sustainability of Pfizer Korea’s hemophilia portfolio. Reporting to the Strategic Alliance & Partnership (SA&P) Lead, the role drives Pfizer’s commercial strategy and stakeholder engagement across the hemophilia landscape in Korea. The role pairs strategic thinking with strong field execution — building a deep understanding of the Hemophilia A landscape, developing key-account engagement strategy, and strengthening the stakeholder relationships that support a sustainable business. As Pfizer’s Hemophilia A market expert, the successful candidate translates field insight into clear commercial direction and works cross-functionally to deliver an integrated portfolio approach. Main Responsibilities / Duties 1.  Hemophilia A Market Navigation & Stakeholder Insight Build and maintain a deep, current understanding of the Korea Hemophilia A landscape — hemophilia treatment centers (HTCs), prescriber decision drivers, prophylaxis paradigms, and the positioning of factor and non-factor therapies (including the incumbent emicizumab franchise). Develop and own a prioritized stakeholder map of high-value Hemophilia A accounts, key opinion leaders, hospital pharmacy and procurement decision-makers, and institutional stakeholders such as the Korea Hemophilia Foundation (KHF). Generate structured field intelligence on competitive dynamics, switching behavior, and unmet need, and translate it into decision-ready input for brand strategy and forecasting. 2.  Key Account Penetration Strategy Design and execute account-level penetration plans for priority Hemophilia A centers, defining the clinical and economic value levers that drive adoption and differentiate Pfizer in target accounts. Establish account-specific engagement and access roadmaps aligned to the brand strategy and the Korean reimbursement (HIRA) environment. Sequence engagement to accelerate early uptake and protect against competitive entrenchment in target accounts. 3.  Strategic Alliance & Business Model Development Identify and assess potential external partnership opportunities that may support portfolio strategy, stakeholder engagement, and sustainable business objectives, using field insight to inform the business rationale and appropriate engagement model. Build transparent, compliant, and purpose-driven engagements with key institutions, academic societies, and clinical opinion leaders, including the Korea Hemophilia Foundation where appropriate, while respecting stakeholder independence and ensuring a legitimate patient, scientific, educational, or access-related purpose. Shape the partnership operating model — governance and ways of working — so that it is sustainable, effective, and fully compliant with Pfizer policy and Korean regulation. Convert field insight into recommendations on go-to-market design, the optimal commercial model, and launch sequencing and investment decisions toward the Hemophilia A winning choice. Partner with Marketing, Market Access, Medical, and Sales to deliver an integrated portfolio narrative across Hemophilia A and B. 4.  Strategic Leadership & Influence Act as the recognized Hemophilia A subject-matter authority within SA&P and the broader Korea commercial organization. Influence cross-functional teams and senior stakeholders without direct authority — bringing a strategist’s framing and a builder’s drive to execution. Role-model Pfizer’s values (Courage, Excellence, Equity, Joy) and an enterprise, One-Pfizer mindset.

Set Education Bachelor’s degree required.

Minimum 8–10 years of pharmaceutical commercial experience, with a substantial track record in Hemophilia — or directly transferable rare-disease / specialty hematology — market development. Demonstrable depth of understanding and credibility with Hemophilia treaters, treatment centers, and the